<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pharmaceutics-13-00387-t0A5" orientation="portrait" position="anchor">
 <object-id pub-id-type="pii">pharmaceutics-13-00387-t0A5_Table A5</object-id>
 <label>Table A5</label>
 <caption>
  <p>Liquid formulations for paediatric use in Research Articles.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formula</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmaceutical Form</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Excipients</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Principle (Dose)</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stability
     <break/>(Stability in Use)
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organic solvent-based formulation of lorazepam (Oral Solution)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG 400 (10% 
     <italic>v/v</italic>), Propylene glycol (3% 
     <italic>m/v</italic>), Glycerol (87% 
     <italic>v/v</italic>) and Orange essence (0.1%)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lorazepam (1 mg/mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children 1 month to 12 years old</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months at 4 °C
     <break/>(Stability in use: 4 weeks)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B119-pharmaceutics-13-00387" ref-type="bibr">119</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution of amlodipine besylate for children</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucrose jarabe (32% 
     <italic>m/v</italic>), Methylparaben (solution 15% 
     <italic>m/v</italic>) (0.3% 
     <italic>m/v</italic>) and Purified water (75%)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amlodipine Besylate (0.5 mg/mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population (children and teenagers)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months at 4 °C
     <break/>(Stability in use: 18 weeks)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B120-pharmaceutics-13-00387" ref-type="bibr">120</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral tizanidine hydrochloride,
     <break/>Formulation for hospital use
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMC (carboxymethyl cellulose) (0.5%), Potassic sorbate (0.15%), Sucralose (0.10%), Citric acid and Purified water</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tizanidine Hydrochloride (1 g/mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70 days at 15–30 °C, 2–8 °C and 40 °C</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B121-pharmaceutics-13-00387" ref-type="bibr">121</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric oral formulation of clonidine hydrochloride</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucrose syrup (20% 
     <italic>v/v</italic>), Raspberry essence (0.05%), Methyl paraben solution 15% (1% 
     <italic>m/v</italic>), Citric acid monohydrate (1% 
     <italic>m/v</italic>), Disodium hydrogen phosphate (1.8% 
     <italic>m/v</italic>) and Purified water
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonidine HCL (50 µg/mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 months at room temperature, protected from light</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B122-pharmaceutics-13-00387" ref-type="bibr">122</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral liquid formulation of clonidine hydrochloride for paediatric patients</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Potassic sorbate, Sucrose and Monohydrate citric acid</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonidine hydrochloride (20 µg/mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Patients (all ages)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 days at 5 °C (cooling) (Stability in use: 42 days at 5 °C)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B123-pharmaceutics-13-00387" ref-type="bibr">123</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric oral formulations of sodium dichloroacetate</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vehicle Mascagni (% 
     <italic>w/v</italic>): Sucralose (0.02%), Hydroxyethyl cellulose (0.2%), Citric acid (0.09%), Sodium citrate (0.09%) and Potassium sorbate (0.18%)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium dichloroacetate (DCA) (9.5% 
     <italic>w</italic>/
     <italic>v</italic>)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Patients </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 months at 4 °C and 25 °C (Stability in use: 1 month to 4 °C)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B124-pharmaceutics-13-00387" ref-type="bibr">124</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Furosemide solutions for personalized paediatric administration</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution (extemporaneous)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solution I: Buffer carbonate-bicarbonate (pH) (10 mL)
     <break/>Excipient for syrup (cps 100 mL) (ACOFARMA): sucrose, water, sorbitol, glycerine, aroma, citric acid, methyl paraben, potassium sorbate, sodium phosphate and colorant. 
     <break/>Solution II: Buffer carbonate-bicarbonate (pH) (10 mL)
     <break/>-Excipient for syrup—without sugars (cps 100 mL) (ACOFARMA): sodium saccharine, xanthan gum, water, sorbitol, glycerine, aroma, citric acid, sodium citrate, methyl paraben, propyl paraben, potassium sorbate, sodium phosphate and colorant. 
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Furosemide (2 mg/mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatrics </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 days at 4 and 25 °C</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B125-pharmaceutics-13-00387" ref-type="bibr">125</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Formulation comprising acetaminophen, especially for paediatrics (PATENT)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution (nano-emulsion)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NF glyceryl mono linoleate (5–30%, preferably 8-26% 
     <italic>w/v</italic>), PEG-35 castor oil (30–60%, preferably 39–46% 
     <italic>w/v</italic>), NF diethylene glycol mono ethyl ether (20–45%, preferably 24–40% 
     <italic>w/v</italic>) and Water
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol (5–18% 
     <italic>w</italic>/
     <italic>v</italic>)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatrics </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B126-pharmaceutics-13-00387" ref-type="bibr">126</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric formulations of ursodeoxycholic acid from oral administration</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerol (20%), Methyl cellulose 1000 (1% 
     <italic>v/v</italic>) and Purified water
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ursodeoxycholic acid (UDCA) (1.5 mg/mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 days at 25 °C or in fridge</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B127-pharmaceutics-13-00387" ref-type="bibr">127</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral paediatric formulation of hydrochlorothiazide</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerol (20%), Methyl cellulose 1000 (1% 
     <italic>v/v</italic>), Citric acid (pH corrector) and Water 
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydrochlorothiazide (2 mg/mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population in general</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 weeks at 5 °C and protected from light</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B128-pharmaceutics-13-00387" ref-type="bibr">128</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension of clindamycin HCL with ion exchange resin for paediatric use</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerine (30% 
     <italic>w/v</italic>), Sucralose (3%), Aroma of maple syrup (7%), Grape aroma (10%), Cremophor RH 40 (15%), Xanthan gum (0.2%) and Deionized water (cps 5 mL)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clindamycin HCL resin (Amberlite IRP 69) (5.5% 
     <italic>w</italic>/
     <italic>v</italic>)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 month at 25 °C</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B129-pharmaceutics-13-00387" ref-type="bibr">129</xref>,
     <xref rid="B130-pharmaceutics-13-00387" ref-type="bibr">130</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isoniazid suspension formulated with cationic resin for paediatric use</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitol solution 70% USP (4.9 mL/ 5 mL), USP monohydrate citric acid (50 mg/5 mL) and USP potassic sorbate (5 mg/5 mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isoniazid resin/Kyron T-134
     <break/>100 mg/5 mL/200 mg/5 mL
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 months at 40 °C (accelerated stability study)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B131-pharmaceutics-13-00387" ref-type="bibr">131</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric xylometazoline nasal spray formulation</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal Spray</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium colatum (105 mg/10 mL), PEG 400 (1.35 mL/10 mL), Sodium carboxy methyl cellulose (10 mg/10 mL), Glycerine (0.15 mL/10 mL), Methyl paraben (3.3 mg/10 mL), Sodium chloride and Purified water (cps 10 mL)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xylometazoline HCl 
     <break/>(5 mg/10 mL)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months at 25 °C</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B132-pharmaceutics-13-00387" ref-type="bibr">132</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
